Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Best Wellness Tracker Keep You On target - 2Step by step instructions to Think about Disc Rates Across Various Banks
- 3First stop, the Moon. Next stop, Mars? Why Nasa's mission matters
- 4Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- 5Science is best communicated through identity and culture – how researchers are ensuring STEM serves their communities
- I'm a hypnotherapist who helps day traders who are losing money. Here's why I think hypnosis works.
- The Most Rousing Ladies Business visionaries of Today
- Inconceivable Spots To Stargaze All over The Planet
- Find the Standards of Viable Refereeing: Settling Debates with Strategy
- The Way to Monetary Freedom: A Viable Aide
- A Gastronomic Experience in Healthy Enjoyments: A Survey of \Nutritious and Tasty\ Solid Cooking Recipe Book
- Vote In favor of Your Favored Kind Of Bites
- If someone's always late, is it time blindness, or are they just being rude?
- Grasping the Basics of Business Land Regulation
